Effects of artemisinin derivatives on malaria transmissibility.
about
Ongoing challenges in the management of malariaRecent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparumStrong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trialImpact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in ZanzibarGametocyte clearance dynamics following oral artesunate treatment of uncomplicated falciparum malaria in Malian childrenPrimaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmissionPrimaquine or other 8-aminoquinoline for reducing P. falciparum transmissionPrimaquine for reducing Plasmodium falciparum transmissionDihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malariaArtemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malariaArtemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malariaArtemisinin-based combination therapy for the treatment of uncomplicated Plasmodium vivax malaria and the prevention of relapsesPrimaquine for reducing transmission of Plasmodium falciparum malariaArtemisinin-based combination therapy for treating uncomplicated malariaArtesunate plus mefloquine versus mefloquine for treating uncomplicated malariaArtesunate-mefloquine for treating uncomplicated malariaTransmission-blocking activities of quinine, primaquine, and artesunateRepeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trialArtemisinin combination therapy for vivax malariaReduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemetherEffect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South AfricaThe role of early detection and treatment in malaria eliminationMonitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in TanzaniaBlocking malaria transmission to Anopheles mosquitoes using artemisinin derivatives and primaquine: a systematic review and meta-analysisGametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient dataHigh efficacy of artemether-lumefantrine and declining efficacy of artesunate + sulfadoxine-pyrimethamine against Plasmodium falciparum in Sudan (2010-2015): evidence from in vivo and molecular marker studiesChloroquine/sulphadoxine-pyrimethamine for gambian children with malaria: transmission to mosquitoes of multidrug-resistant Plasmodium falciparumGametocytaemia after drug treatment of asymptomatic Plasmodium falciparumOpen-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malariaModelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensityImpact of changing drug treatment and malaria endemicity on the heritability of malaria phenotypes in a longitudinal family-based cohort studyActivity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence "transmission blocking" assayRisk factors for Plasmodium falciparum gametocyte positivity in a longitudinal cohortActivity of Herbal Medicines on Plasmodium falciparum Gametocytes: Implications for Malaria Transmission in GhanaTherapeutic Efficacy of Artemether-Lumefantrine (Coartem®) in Treating Uncomplicated P. falciparum Malaria in Metehara, Eastern Ethiopia: Regulatory Clinical StudySMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology.Molecular surveillance for drug-resistant Plasmodium falciparum in clinical and subclinical populations from three border regions of Burma/Myanmar: cross-sectional data and a systematic review of resistance studiesChanging patterns of clinical malaria since 1965 among a tea estate population located in the Kenyan highlandsPersistent ICT malaria P.f/P.v panmalarial and HRP2 antigen reactivity after treatment of Plasmodium falciparum malaria is associated with gametocytemia and results in false-positive diagnoses of Plasmodium vivax in convalescence.The drug sensitivity and transmission dynamics of human malaria on Nias Island, North Sumatra, Indonesia.
P2860
Q17485687-1FF9300B-ED67-4D41-9F31-93BE4B9EA237Q21032477-779620F6-E54B-4D71-90A4-AE30316E8B06Q21562479-5208339B-E8C7-4FB8-A3C8-7AFDE618F0DFQ22061782-2E411695-41D4-42D1-8879-4A7800996961Q22773191-D7EF2D37-BDB6-45D4-9F1B-DEE77D3384D2Q24188070-AB201B41-C9EB-44A0-BC5B-6480A044218EQ24193716-21A4CDC8-16E3-41F2-BBDD-823F952AC498Q24200471-4330388B-E7BA-4141-8981-DD5EA677217FQ24201077-1D2F76FE-84CF-4E10-AD1B-1B2EB8E91AE0Q24202910-6D9D6C3A-0DB6-42C4-9375-E2777882CF2AQ24235351-3ADA1AB4-8150-41F6-A520-4DAA1E54A8AEQ24236067-181648B9-60E1-4DFC-A656-8F62637F4542Q24241596-E226ED39-EE1C-497D-8BB6-55B3FCD60818Q24241785-3705EF6C-239D-40C9-AF6B-75CF48A07318Q24245347-3EE12688-670D-4B1A-834D-DBD390665DE7Q24247831-9DD5937A-692A-4CA0-B814-646172910A51Q24548262-EBB4BF55-36FF-4AF4-9179-1913D5DFA5A8Q24597403-DFDCBE3E-C0D2-45CF-9BB3-BCF2DCEC00DDQ24622539-53937B47-2711-4C62-8413-1B9F963485B3Q24792020-14302931-B3A3-4B7C-AE63-5352781A7167Q24810617-844EA2CB-628F-4931-9E18-77945691CAE1Q26740068-184A346C-3EB1-4402-B2A0-699D977068D7Q26820807-4D2E995B-D3BB-442F-88DD-CF3007A14158Q27014789-C21D4BC2-4EA5-465C-9B09-6D500D6BACB9Q28068072-E276F1C2-D6CB-4634-84DF-3F297A137D78Q28125935-420D8E6A-B9E6-4E6F-9075-1B3780EE2A61Q28469025-F0132456-4B5E-48DD-97EF-A94DA663215BQ28469180-10CCFAE1-8350-4298-86B9-66C9827DF67CQ28472247-D9FDE45B-7E0D-4438-BEE2-7B3793D20189Q28474141-6607B8DD-9BAB-4E17-AA20-29BD0092D61FQ28477767-3A953AA4-56DF-450A-AE70-E4FE01187825Q28482292-1A3099B9-7541-49CF-A476-DFDBABA02C55Q28545275-6CDFCC0A-3248-4742-966C-B981D4260CD3Q28550911-F3EA62AF-9D5C-4EFE-BEC6-BA9913F84200Q28551712-716B1CB8-1CE3-4D75-907E-F4F32A975617Q30396615-1616528D-6D54-48C7-8E0D-57BC44AD9D02Q30568502-B83DBE62-FC4F-46F4-B877-FB408A3BDCF3Q30611242-A1BDF144-33DE-4702-9A45-E21D0A16CE34Q30982557-547CA20E-2910-4308-ACAF-FA466022A362Q31105390-AD622939-FBED-4356-97E0-7489FD09CEFD
P2860
Effects of artemisinin derivatives on malaria transmissibility.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Effects of artemisinin derivatives on malaria transmissibility.
@en
Effects of artemisinin derivatives on malaria transmissibility.
@nl
type
label
Effects of artemisinin derivatives on malaria transmissibility.
@en
Effects of artemisinin derivatives on malaria transmissibility.
@nl
prefLabel
Effects of artemisinin derivatives on malaria transmissibility.
@en
Effects of artemisinin derivatives on malaria transmissibility.
@nl
P2093
P50
P1433
P1476
Effects of artemisinin derivatives on malaria transmissibility.
@en
P2093
C Luxemburger
T Chongsuphajaisiddhi
P304
P356
10.1016/S0140-6736(96)91488-9
P407
P577
1996-06-01T00:00:00Z